Satterlee advised Y-mAbs Therapeutics, Inc. on its follow-on public offering of 5,134,750 shares of common stock at a price of $28.00, including the full exercise of the underwriters’ option to purchase 669,750 additional shares, for gross proceeds of approximately $144 million, which closed on November 1, 2019. Y-mAbs trades on the Nasdaq Global Select Market under the symbol “YMAB.”
Morgan Stanley, J.P. Morgan and BofA Securities served as joint book-running managers for the offering. Wedbush PacGrow and H.C. Wainwright & Co. acted as co-managers for the offering.
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Satterlee has represented Y-mAbs in other matters since its inception in April 2015, including its earlier funding rounds totaling approximately $120 million and its initial public offering of $110 million.
For more information, please see Y-mAbs’ press release.